Keywords
How to Cite
Abstract
Aim: We studied the intergenic interactions and the contribution of polymorphic loci for GSTT1, GSTM1, GSTP1 genes in the formation of predisposition to breast cancer (ВС) in women of Kyrgyz nationality.
Material and method: The study included 87 women of the Kyrgyz ethnic group with the morphologically verified diagnosis of BC and 96 women without cancer and chronic diseases. Genotyping of single-nucleotide polymorphisms (SNPs) was performed using PCR-RFLP for rs1695 GSTP1 gene. Deletion polymophisms in GSTT1 and GSTM1 genes were determined using allele-specific real-time PCR. Analysis of the intergenic interactions conducted with MDR 3.0.2 software.
Results: Among women of Kyrgyz nationality, deletion of the GSTM1 gene region is a genetic marker associated with an increased likelihood of developing breast cancer (OR = 2.18, 95% CI 1.38-3.44), p = 0.0007). The absence of deletion in this gene is associated with a protective effect. Analysis of polymorphic markers (GSTT1 gene) and p.Ile105Val (GSTP1 gene) did not reveal statistically significant differences in the frequency distribution of genotypes and alleles between breast cancer patients and women from the comparison group (p > 0.05). Analysis of intergenic interactions using MDR analysis showed that, with the simultaneous presence of the Arg/Gln genotypes (XRCC1 gene) and (GSTM1 gene), the probability of developing breast cancer was - OR = 2.63.
Conclusions: Deletion of the GSTM1 gene and combinations of the Arg/Gln genotypes (XRCC1 gene) and (GSTM1 gene) may contribute to the genetic susceptibility of BC in Kyrgyz women.
References
Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLoBoCAN 2012. Int. J. Cancer. 2015, 136:359-386. DOI: 10.1002/ijc.29210.
Igisinov N., Kokteubaeva N., Kudaibergenova I. Epidemiology of breast cancer in females of reproductive age in Kyrgyzstan. Asian Pac J Cancer Prev. 2005, 6:36-39.
Пузырев В.П., Кучер А.Н. Эволюционно-онтогенетические аспекты патогенетики хронических болезней человека. Генетика. 2011. 47,12:1573-1585.
Fachal L., Dunning A.M. From candidate gene studies to GWAS and post-GWAS analyses in breast cancer. Curr Opin Genet Dev. 2015,30:32-41. DOI: 10.1016/j. gde.2015.01.004.
Raunio H., Husgafvel-Pursiainen K., Anttila S. et al. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review. Gene. 1995,159: 113-121. DOI: 10.1016/0378-1119(94)00448-2.
Афанасьева И.С., Спицын В.А. Наследственный полиморфизм глутатион-трансферазы печени человека в норме и при алкогольном гепатите. Генетика. 1990, 26:1309-1315.
Baranov V.S., Ivaschenko T., Bakay B. et al. Proportion of the GSTM1 0/0 genotype in some Slavic populations and its correlation with cystic fibrosis and some multifactorial diseases. Hum. Genet. 1996, 97: 516-520. DOI: 10.1007/ bf02267078.
Ryberg D., Skaug V., Hewer A. et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis. 1997, 18: 1285-1289. DOI: 10.1093/carcin/18.7.1285.
Duggan C., Ballard-Barbash R., Baumgartner R.N. et al. Associations between null mutations in GSTT1 and GSTM1, the GSTP1 Ile(105)Val polymorphism, and mortality in breast cancer survivors. Springerplus. 2013, 11: 1-9. DOI: 10.1186/2193-1801-2-450.
Spurdle A.B., Fahey P., Chen X. et al. Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2010, 122: 281-285. DOI: 10.1007/s10549-009-0601-0.
Смирнова Е.Г., Кипень В.Н., Мельнов С.Б., Мохорт А.А. Полиморфизм генов глутатион-трансфераз при раке почки. Молекулярная и прикладная генетика. 2017, 23: 75-82.
Бурденный А.М., Казубская Т.П. Брага Э.А. и др. Ассоциация полиморфных маркеров генов биотрансформации ксенобиотиков с раком молочной железы у женщин московского региона. Мол. медицина. 2012, 5: 5-10.
Saxena A., Dhillon V.S., Raish M. et al. Detection and relevance of germline genetic polymorphisms in glutathione S-transferases (GSTs) in breast cancer patients from northern Indian population. Breast Cancer Res. Treat. 2009, 115: 537-543. DOI: 10.1007/s10549- 008-0098-y.
Isakova J., Talaibekova E., Aldasheva N. et al. The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females. BMC Cancer. 2017, 17(1):1-7. DOI: 10.1186/s12885-017-3762-y.
Исакова Ж.Т, Кипень В.Н., Талайбекова Э.Т. и др. Межгенные взаимодействия и вклад генов ТP53, XRCC1, TNFa, HMMR, MDM2 и PALB2 в формирование предрасположенности к раку молочной железы у женщин кыргызской национальности. Вопросы онкологии. 2019, 65(3): 357-367.
Zgheib N.K., Shamseddine A.A., Geryess E. et al. Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women. Mutat. Res. 2013, 747: 40-47. DOI: 10.1016/j.mrfmmm.2013.04.004.
Sohail A., Kanwal N., Ali M. et al. Effects of glutathione-S-transferase polymorphisms on the risk of breast cancer: a population-based case-control study in Pakistan. Environ. Toxicol. Pharmacol. 2013, 35: 143-153. DOI: 10.1016/j. etap.2012.11.014.
Hashemi M., Eskandari-Nasab E., Fazaeli A. et al. Association between polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer risk in a sample Iranian population. Biomark. Med. 2012, 6: 797-803. DOI: 10.2217/bmm.12.61.
Qiu L.X., Yuan H., Yu K.D. et al. Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: a meta-analysis involving 46,281 subjects. Breast Cancer Res. Treat. 2010, 121: 703-708. DOI: 10.1007/s10549- 009-0636-2.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020